1
|
Holubová M, Nagelová V, Lacinová Z, Haluzík M, Sýkora D, Moulin A, Blayo AL, Fehrentz JA, Martinez J, Stofkova A, Jurčovičová J, Zelezná B, Maletínská L. Triazole GHS-R1a antagonists JMV4208 and JMV3002 attenuate food intake, body weight, and adipose tissue mass in mice. Mol Cell Endocrinol 2014; 393:120-8. [PMID: 24953973 DOI: 10.1016/j.mce.2014.06.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 05/19/2014] [Accepted: 06/05/2014] [Indexed: 12/29/2022]
Abstract
The only peripherally released orexigenic hormone, ghrelin, plays a key role in food intake and body weight regulation. Antagonizing the ghrelin receptor, GHS-R1a, represents a promising approach for anti-obesity therapy. In our study, two novel GHS-R1a antagonists JMV4208 and JMV3002, which are trisubstituted 1,2,4-triazoles, decreased food intake in fasted lean mice in a dose-dependent manner, with ED50 values of 5.25 and 2.05 mg/kg, respectively. Both compounds were stable in mouse blood, with half-lives of 90 min (JMV4208) and 60 min (JMV3002), and disappeared from the blood 8h after administration. Fourteen days of treatment with the ghrelin antagonists (20 mg/kg twice a day) decreased food intake, body weight and adipose tissue mass in mice with diet-induced obesity (DIO). These results are likely attributable to an impact on food intake reduction and an attenuated expression of the lipogenesis-promoting enzymes (acetyl-CoA carboxylase 1 in subcutaneous fat and fatty acid synthase in subcutaneous and intraperitoneal fat). The decrease in fat mass negatively impacted circulating leptin levels. These data suggest that JMV4208 and JMV3002 could be useful therapeutic agents for the treatment of obesity.
Collapse
Affiliation(s)
- M Holubová
- Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic; Third Department of Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - V Nagelová
- Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic
| | - Z Lacinová
- Third Department of Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - M Haluzík
- Third Department of Medicine, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
| | - D Sýkora
- Institute of Chemical Technology, Department of Analytical Chemistry, Prague, Czech Republic
| | - A Moulin
- IBMM UMR 5274, CNRS - Universités Montpellier 1- Montpellier 2, Faculté de Pharmacie, Montpellier, France
| | - A L Blayo
- IBMM UMR 5274, CNRS - Universités Montpellier 1- Montpellier 2, Faculté de Pharmacie, Montpellier, France
| | - J A Fehrentz
- IBMM UMR 5274, CNRS - Universités Montpellier 1- Montpellier 2, Faculté de Pharmacie, Montpellier, France
| | - J Martinez
- IBMM UMR 5274, CNRS - Universités Montpellier 1- Montpellier 2, Faculté de Pharmacie, Montpellier, France
| | - A Stofkova
- Department of Normal, Pathological and Clinical Physiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - J Jurčovičová
- Department of Normal, Pathological and Clinical Physiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
| | - B Zelezná
- Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic
| | - L Maletínská
- Institute of Organic Chemistry and Biochemistry, AS CR, Prague, Czech Republic.
| |
Collapse
|
2
|
Spolcová A, Holubová M, Mikulášková B, Nagelová V, Stofková A, Lacinová Z, Jurčovičová J, Haluzík M, Maletínská L, Zelezná B. Changes in FGF21 serum concentrations and liver mRNA expression in an experimental model of complete lipodystrophy and insulin-resistant diabetes. Physiol Res 2014; 63:483-90. [PMID: 24908095 DOI: 10.33549/physiolres.932714] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Patients with obesity and type 2 diabetes often display high levels of the anti-diabetic factor fibroblast growth factor-21 (FGF21), suggesting that the overproduction of FGF21 may result from increased adiposity in an attempt by white adipose tissue (WAT) to counteract insulin resistance. However, the production of FGF21 diabetes in the absence of WAT has not been examined. In this study, we investigated the effects of lipodystrophy in A-ZIP F-1 mice on FGF21 production in relation to diabetes. A-ZIP F-1 mice displayed high FGF21 plasma levels resulting from enhanced FGF21 mRNA expression in the liver. Concomitant enhancement of FGF21 receptor (FGFR1) and glucose transporter 1 (GLUT-1) mRNA expression was observed in the muscles of A-ZIP F-1 mice. Furthermore, the activation of hypothalamic NPY and AgRP mRNA expression positively correlated with plasma levels of FGF21 but not active ghrelin. Our study demonstrates that an increased FGF21 plasma level in lipodystrophic A-ZIP F-1 mice results mainly from up-regulated liver production but does not suffice to overcome the lipodystrophy-induced severe type 2-diabetes and insulin resistance in the liver linked to the augmented liver fat deposition.
Collapse
Affiliation(s)
- A Spolcová
- Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic.
| | | | | | | | | | | | | | | | | | | |
Collapse
|